Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137

Medulloblastoma (MB) is the most common malignant pediatric brain tumor that can be categorized into four major molecular subgroups. Group 3 MB with MYC amplification (MYCamp-G3-MB) has been shown to be highly aggressive and exhibited worst prognosis, indicating the need for novel effective therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiajia, Sui, Yi, Li, Qifeng, Zhao, Yang, Dong, Xiaoshu, Yang, Jian, Liang, Zhuangzhuang, Han, Yipeng, Tang, Yujie, Ma, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710710/
https://www.ncbi.nlm.nih.gov/pubmed/33268769
http://dx.doi.org/10.1038/s41419-020-03201-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710710/
https://www.ncbi.nlm.nih.gov/pubmed/33268769
http://dx.doi.org/10.1038/s41419-020-03201-6

Ejemplares similares